Journal of Proteomics & Bioinformatics
Open Access
ISSN: 0974-276X
+44 1223 790975
ISSN: 0974-276X
+44 1223 790975
Byung Woo Kim, Soojung Jin, You Na Oh, and Hyun Ju Kwon
Dong-Eui University, South Korea
Posters & Accepted Abstracts: J Proteomics Bioinform
Osmanthus matsumuranus, a species of Oleaceae, is found in East Asia and Southeast Asia. The bioactivities of O. matsumuranus have not yet been fully understood. Here, we studied on the molecular mechanisms underlying anticancer effect of ethanol extract of O. matsumuranus (EEOM). EEOM showed the cytotoxic activities in a dose-dependent manner in various cancer cell lines, but not in normal cells, and HepG2 cells were most susceptible to EEOM-induced cytotoxicity. EEOM induced G2/M arrest in HepG2 cells associated with decreased expression of cyclin-dependent kinase 1 (CDK1), cyclin A and cylcin B, and increased expression of phospho-checkpoint kinase 2, p53 and CDK inhibitor p21. Immunofluorescence staining showed that EEOM-treated HepG2 increased doublet nuclei and condensed actin, resulting in cell rounding. Furthermore, EEOM-mediated apoptosis was determined by Annexin V staining, chromatin condensation and DNA fragmentation. EEOM caused upregulation of FAS and Bax, activation of caspase-3, -8, -9, and fragmentation of poly ADP ribose polymerase. These results suggest that EEOM efficiently inhibits proliferation of HepG2 cells by inducing both G2/M arrest and apoptosis via intrinsic and extrinsic pathways, and EEOM may be a possible candidate for the anticancer drug development. Recent Publications: 1. Boutros R, Lobjois V and Ducommun B (2007) CDC25 phosphatases in cancer cells: key player? Good targets? Nat. Rev. Cancer 7: 495-507. 2. Fulda S and Debatin K M (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 25: 4798-4811. 3. Singh S, Singh P P, Roberts L R and Sanchez W (2014) Chemopreventive strategies in hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 11: 45-54. 4. Stewart Z A, Westfall M D, Pietenpol J A (2003) Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol. Sci. 24: 139-145. 5. Taylor W R and Stark G R (2001) Regulation of the G2/M transition by p53. Oncogene. 20: 1803-1815.
Byung Woo Kim has completed his PhD in Pharmacology from Busan University, Busan, Republic of Korea. He is currently working as a Professor at Division of Applied Bioengineering, Biopharmaceutical Engineering Major, Dong-Eui University and as the Director of Blue-Bio Industry Regional Innovation Center, Dong-Eui University, Busan, Korea. His research field is Pharmaceutical biotechnology of natural Products.